The 11 currently reportable or Tier 1/actionable variants for NSCLC (ALK, EGFR, BRAF, KRAS, NTRK1, NTRK2, NTRK3, ROS, RET, MET and ERBB2) were verified and commercial control material was utilised to supplement the verification. Here, KRAS is linked to non-small cell lung carcinoma.